Please use this identifier to cite or link to this item: http://www.repositorio.ufop.br/jspui/handle/123456789/14035
Title: Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma.
Authors: Magalhães, Giselle Santos
Gregório, Juliana Fabiana
Ribeiro, Arthur Tonani Pereira Cançado
Baroni, Isis Felippe
Vasconcellos, Ana Victoria de Oliveira
Nakashima, Gabriela Pansanato
Oliveira, Isabel Fusaro Aguiar
Matos, Natália Alves de
Castro, Thalles de Freitas
Bezerra, Frank Silva
Sinisterra, Ruben Dario
Pinho, Vanessa
Teixeira, Mauro Martins
Santos, Robson Augusto Souza dos
Machado, Maria da Glória Rodrigues
Santos, Maria José Campagnole dos
Keywords: Resolution of inflammation
Allergic lung inflammation
Lipopolysaccharide(LPS)
Issue Date: 2021
Citation: MAGALHÃES, G. S. et al. Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. Frontiers in Pharmacology, v. 12, p. 1-9, mar. 2021. Disponível em: <https://www.frontiersin.org/articles/10.3389/fphar.2021.557962/full>. Acesso em: 10 jun. 2021.
Abstract: The presence of eosinophils and neutrophils in the lungs of asthmatic patients is associated with the severity of the disease and resistance to corticosteroids. Thus, defective resolution of eosinophilic and neutrophilic inflammation is importantly related to exacerbation of asthma. In this study, we investigated a therapeutic action of angiotensin-(1-7) (Ang-(1-7)) in a model of asthma induced by ovalbumin (OVA) and lipopolysaccharide (LPS). Balb-c mice were sensitized and challenged with OVA. Twentythree hours after the last OVA challenge, experimental groups received LPS, and 1 h and 7 h later, mice were treated with oral formulation of Ang-(1-7). On the next day, 45 h after the last challenge with OVA, mice were subjected to a test of motor and exploratory behavior; 3 h later, lung function was evaluated, and bronchoalveolar lavage fluid (BALF) and lungs were collected. Motor and exploratory activities were lower in OVA + LPSchallenged mice. Treatment with Ang-(1-7) improved these behaviors, normalized lung function, and reduced eosinophil, neutrophil, myeloperoxidase (MPO), eosinophilic peroxidase (EPO), and ERK1/2 phosphorylation (p-ERK1/2) in the lungs. In addition, Ang-(1-7) decreased the deposition of mucus and extracellular matrix in the airways. These results extended those of previous studies by demonstrating that oral administration of Ang-(1-7) at the peak of pulmonary inflammation can be valuable for the treatment of neutrophil- and eosinophil-mediated asthma. Therefore, these findings potentially provide a new drug to reverse the natural history of the disease, unlike the current standards of care that manage the disease symptoms at best.
URI: http://www.repositorio.ufop.br/jspui/handle/123456789/14035
metadata.dc.identifier.doi:  https://doi.org/10.3389/fphar.2021.557962
ISSN: 1663-9812
metadata.dc.rights.license: This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Source: The article PDF.
Appears in Collections:DECBI - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
OralFormulationAngiotensin.pdf1,94 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.